Pharmaceutical manufacturers are deploying aggressive capital outlays to expand contract development and manufacturing organization (CDMO) capabilities for metabolic therapies. The rapid surge in prescription volume has exposed severe bottlenecks in specialized sterile fill-finish processing and peptide synthesis infrastructure.
Supply Chain Capital Expenditures
Leading pharmaceutical firms have committed over $15 billion toward greenfield facility construction to alleviate persistent stockouts. Industry analysts project that localized manufacturing hubs will be critical to lowering logistics overhead and satisfying mandated public health supply contracts over the next three years.